The use of copper-67 radioisotope has been severely limited up to this point because it has traditionally been difficult to obtain, was often not very pure, and also very expensive. Iotron are working with parners to commercialize a new production method based on enriched zinc-68 targets and a compact electron beam accelerator.
A patented sublimation process separates the copper-67 from the target which also facilitates rapid and efficient enriched target material recycling. The resulting copper-67 has high specific activity and low chemical and radiochemical impurity levels. The four granted US patents are provided below (Europe and Japan patents also granted):
Iotron Medical, a spin-out business of Iotron Industries - providing innovative solutions using electron beam for more than 25 years
Canadian Isotope Innovations, operating the most capable photonuclear electron accelerator in production in North America today
If you have any queries or wish to contact us:
For partnering opportunities:
To buy radioisotope: